Thyrocare

Tests you can trust

Name : XXXXXXXX

Date : XXXXXXXXX

Test Asked : Jaanch Sle Panel

Report Status : Complete Report

Dummy Report



First National Diagnostic Chain to have **100% of its Labs with NABL Accreditation#**

98% Reports released within **06 Hours** of sample reaching the lab+

9 out of 10 Doctors Trust that Thyrocare reports are Accurate & Reliable*

1200+ Tests & Profiles

Temperature-Controlled Sample Logistics | Unique Barcode Tracking | Fully Automated Machines Inspected Daily | Abnormal Values Re-Checked Twice | Reports Verified By Expert MD Pathologists Stationed at Every Lab

Your reports are digitally verifiable

Scan the QR code inside the report to check authenticity of reported values

QR code will remain active for 30 days from report release date

Accredited by

NABL From 2005#

ISO 9001: 2015 - From 2015

CAP From 2007-

Thyrocare
Tests you can trust

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703. 9870666333 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation#

Patient Name : XXXXXXXXXXXX
Referred By : XXXXXXXXXXXX
Sample Collected At : XXXXXXXXXXXX

Tests Done : **JAANCH SLE PANEL**

Report Availability Summary

Note: Please refer to the table below for status of your tests.

5 Ready | **0** Ready with Cancellation | **0** Processing | **0** Cancelled in Lab

TEST DETAILS	REPORT STATUS
JAANCH SLE PANEL	Ready
ANTI - DSDNA	Ready
SM (SMITH) ANTIBODY, IGG	Ready
ANTI NUCLEAR ANTIBODIES (ANA)	Ready
ANTI PHOSPHOLIPID ANTIBODY (APL) - IGG	Ready
ANTI PHOSPHOLIPID ANTIBODY (APL) - IGM	Ready

Dummy Report

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703. 9870666333 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation#

Patient Name : XXXXXXXXXXXX
Referred By : XXXXXXXXXXXX
Sample Collected At : XXXXXXXXXXXX

Tests Done : **JAANCH SLE PANEL**

Tests Outside Reference Range

Note: Please refer to the table below for tests outside reference range.

Test Name	Observed Value	Units	Bio. Ref. Interval.
ARTHRITIS			
ANTI NUCLEAR ANTIBODIES (ANA)	**14.87**	OD Ratio	0.001-0.90

Dummy Report

Disclaimer: The above listed is the summary of the parameters with values outside the BRI. For detailed report values, parameter correlation and clinical interpretation, kindly refer to the same in subsequent pages.

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703. 9870666333 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation#

Patient Name	: XXXXXXXXXXXX	Sample Collected on (SCT)	: XXXXXXXXXXXX
Referred By	: XXXXXXXXXXXX	Sample Received on (SRT)	: XXXXXXXXXXXX
Sample Collected At	: XXXXXXXXXXXX	Report Released on (RRT)	: XXXXXXXXXXXX
		Sample Type | Barcode	: XXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
SM (SMITH) ANTIBODY, IGG	ELISA	< 100	Ab Index

Bio. Ref. Interval. :-

Normal range: < 0.9

Interpretation:

Antibody Index Range || Interpretation
< 0.9 || No detectable Sm antibodies
0.9 – 1.1 || Borderline - follow up testing recommended if clinically indicated
> 1.1 || Presence of Sm antibodies, suggestive of autoimmune activity (e.g., SLE or other MTDs, mixed connective tissue disorders)

Clinical Significance:
1.The presence of Sm antibodies is a highly specific marker for Systemic Lupus Erythematosus (SLE).
2.These antibodies are rarely detected in other autoimmune diseases or in healthy individuals.
3.Therefore, this test is valuable for the diagnosis and prognosis of autoimmune conditions such as SLE, mixed connective tissue disease, Sjogren syndrome, scleroderma, and polymyositis/dermatomyositis.
4.SLE patients with presence of Anti Sm antibodies usually have associated renal disease and / or disorders of central nervous system.

Limitations:
1.The test results obtained serve only as an aid to diagnosis and should be interpreted in relation to the patient's history, physical findings and other diagnostic procedures. Lipemic or hemolyzed samples may cause erroneous results.
2.Rarely, some sample specific factors and cross reactivity may interfere with the results
3.This is a screening test, to be confirmed by a confirmatory test if clinically indicated.

Please correlate with clinical conditions.

Method:- ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)

Dummy Report

Tests Done : JAANCH SLE PANEL

Report Remarks : Labcode:2001001574/IT001

Doctor 1 Sign

Doctor 2 Sign

Patient Name	: XXXXXXXXXXXX	Sample Collected on (SCT)	: XXXXXXXXXXXX
Referred By	: XXXXXXXXXXXX	Sample Received on (SRT)	: XXXXXXXXXXXX
Sample Collected At	: XXXXXXXXXXXX	Report Released on (RRT)	: XXXXXXXXXXXX
		Sample Type | Barcode	: XXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
ANTI PHOSPHOLIPID ANTIBODY (APL) - IGG	E.L.I.S.A	< 5	AU/mL

Bio. Ref. Interval. :-

Normal : <10
Elevated : >=10
Clinical Significance :
Anti-Phospholipid Antibodies are frequently found in Sera of patients Systemic Lupus Erythematosus (SLE) and related diseases. Many studies have shown a correlation between these Autoantibodies and an enhanced incidence of Thrombosis, Thrombocytopenia and Habitual Abortions.
This assay is an aid in the diagnosis and risk estimation of Thrombosis in patients with systemic lupus erythematosus and Antiphospholipid Syndrome (APS).
Technical Note: Antiphospholipid Antibody detection ELISA is a Solid Phase Enzyme Immunoassay for the quantitative detection of antibodies against Phospholipids in human serum.
Each well is coated with highly purified bovine Cardiolipin + B2-Glycoprotein 1,Phosphatidyl Serine, Phosphatidyl Inositol, Phosphatidyl Ethanolamin, Phosphatidyl Choline and Sphingomyelin.
External Quality Control Program Participation: College of American Pathologists (CAP):
Special Immunology Survey; CAP Certification Number: 7193855-01

Please correlate with clinical conditions.

Method:- INDIRECT SOLID PHASE IMMUNOASSAY

Dummy Report

Tests Done : JAANCH SLE PANEL

Report Remarks : Labcode:2001001574/IT001

Doctor 1 Sign **Doctor 2 Sign**

Patient Name	: XXXXXXXXXXXX	Sample Collected on (SCT)	: XXXXXXXXXXXX
Referred By	: XXXXXXXXXXXX	Sample Received on (SRT)	: XXXXXXXXXXXX
Sample Collected At	: XXXXXXXXXXXX	Report Released on (RRT)	: XXXXXXXXXXXX
		Sample Type | Barcode	: XXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
ANTI PHOSPHOLIPID ANTIBODY (APL) - IGM	E.L.I.S.A	< 5	AU/mL

Bio. Ref. Interval. :-

Normal : <10
Elevated : >=10
Clinical Significance:
Anti-Phospholipid Antibodies are frequently found in Sera of patients Systemic Lupus Erythematosus (SLE) and related diseases. Many studies have shown a correlation between these Autoantibodies and an enhanced incidence of Thrombosis, Thrombocytopenia and Habitual Abortions.
This assay is an aid in the diagnosis and risk estimation of Thrombosis in patients with systemic lupus erythematosus and Antiphospholipid Syndrome (APS).
Technical Note: Antiphospholipid Antibody detection ELISA is a Solid Phase Enzyme Immunoassay for the quantitative detection of antibodies against Phospholipids in human serum.
Each well is coated with highly purified bovine Cardiolipin + B2-Glycoprotein 1,Phosphatidyl Serine, Phosphatidyl Inositol, Phosphatidyl Ethanolamin, Phosphatidyl Choline and Sphingomyelin.
External Quality Control Program Participation: College of American Pathologists (CAP):
Special Immunology Survey; CAP Certification Number: 7193855-01

Please correlate with clinical conditions.

Method:- INDIRECT SOLID PHASE IMMUNOASSAY

Dummy Report

Tests Done : JAANCH SLE PANEL

Report Remarks : Labcode:2001001574/IT001

Doctor 1 Sign **Doctor 2 Sign**

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703. 9870666333 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation#

Patient Name	: XXXXXXXXXXXX	Sample Collected on (SCT)	: XXXXXXXXXXXX
Referred By	: XXXXXXXXXXXX	Sample Received on (SRT)	: XXXXXXXXXXXX
Sample Collected At	: XXXXXXXXXXXX	Report Released on (RRT)	: XXXXXXXXXXXX
		Sample Type | Barcode	: XXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
ANTI - DSDNA	E.L.I.S.A	< 12.5	U/ml

Bio. Ref. Interval. :

Negative : < 25
Equivocal : 25.0 - 34.9
Positive : > 35

Clinical Significance:
-Anti ds- DNA is present in 50-70% patients with systemic lupus erythematosus (SLE). The presence of anti ds DNA is one of the diagnostic criteria for SLE.
The reactivity of antibodies to dsDNA may fluctuate with SLE disease activity. Increasing reactivity may be associated with flares while a decline or seronegativity may indicate response to treatment or disease remission.
-A positive result for double-stranded DNA (dsDNA) IgG antibodies in the appropriate clinical context is suggestive of systemic lupus erythematosus (SLE)
-Weak-positive dsDNA IgG antibody results have a low-positive predictive value for SLE
-Negative results do not rule out a diagnosis of SLE.
The test results obtained using this kit serve only as an aid to diagnosis and should be interpreted in conjunction with clinical history and other findings.
References :
1. Kit Insert.
2. Wong KH; Lawton JW; Cheng SK; Lee SS; Lau CS. Measurement of anti-dsDNA: a comparative study of two ELISA and the Crithidia assay. Pathology 1998; 30(1):57-61.

Method : SOLID PHASE ENZYME IMMUNOASSAY

Please correlate with clinical conditions.

Dummy Report

Tests Done : JAANCH SLE PANEL

Report Remarks : Labcode:2001001574/IT001

Doctor 1 Sign **Doctor 2 Sign**

Thyrocare Technologies Limited, D-37/3, TTC MIDC, Turbhe, Navi Mumbai - 400 703. 9870666333 wellness@thyrocare.com

First National Diagnostic Chain to have 100% of its Labs with NABL Accreditation#

Patient Name	: XXXXXXXXXXXX	Sample Collected on (SCT)	: XXXXXXXXXXXX
Referred By	: XXXXXXXXXXXX	Sample Received on (SRT)	: XXXXXXXXXXXX
Sample Collected At	: XXXXXXXXXXXX	Report Released on (RRT)	: XXXXXXXXXXXX
		Sample Type | Barcode	: XXXXXXXXXXXX

TEST NAME	TECHNOLOGY	VALUE	UNITS
ANTI NUCLEAR ANTIBODIES (ANA)	**E.L.I.S.A**	**14.87**	**OD Ratio**

Bio. Ref. Interval. :

Negative: <0.90
Equivocal : 0.90 - 1.10
Positive: >1.11

Clinical Significance:
Anti-nuclear antibodies (ANA) are autoantibodies directed against nuclear components and are commonly associated with autoimmune diseases such as systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), systemic sclerosis, Sjögren's syndrome, and rheumatoid arthritis.

However, ANA positivity is not specific to any one condition and may also be seen in healthy individuals, especially the elderly, or in cases of infections, malignancies, or drug-induced autoimmunity.

Equivocal results may require repeat testing or additional evaluation with specific antibody panels (e.g., anti-Sm, anti-RNP, anti-Ro, anti-La) for diagnostic clarification. A negative ANA test does not completely rule out autoimmune disease, particularly in early stages or when non-ANA-specific autoantibodies are involved. The final diagnosis should be made by the physician based on the overall clinical picture and appropriate correlation with additional investigations.

Note: Hemolysis, lipemia, icterus, microbial contamination, high-dose biotin, or heterophile antibodies may interfere with test accuracy and may lead to false-positive or false-negative results.

Method : INDIRECT SOLID PHASE IMMUNOASSAY

Please correlate with clinical conditions.

Dummy Report

~~ End of report ~~

Tests Done : JAANCH SLE PANEL

Report Remarks : Labcode:2001001574/IT001

Doctor 1 Sign **Doctor 2 Sign**

CONDITIONS OF REPORTING

- The reported results are for information and interpretation of the referring doctor only.
- It is presumed that the tests performed on the specimen belong to the patient; named or identified.
- Results of tests may vary from laboratory to laboratory and also in some parameters from time to time for the same patient.
- Should the results indicate an unexpected abnormality, the same should be reconfirmed.
- Only such medical professionals who understand reporting units, reference ranges and limitations of technologies should interpret results.
- This report is not valid for medico-legal purpose.
- Neither Thyrocare, nor its employees/representatives assume: (a) any liability, responsibility for any loss or damage that may be incurred by any person as a result of presuming the meaning or contents of the report, (b) any claims of any nature whatsoever arising from or relating to the performance of the requested tests as well as any claim for indirect, incidental or consequential damages. The total liability, in any case, of Thyrocare shall not exceed the total amount of invoice for the services provided and paid for.
- Thyrocare Discovery video link :- https://youtu.be/nbdYeRgYyQc

EXPLANATIONS

- Majority of the specimen processed in the laboratory are collected by Pathologists and Hospitals we call them as "Clients".
- **Name** - The name is as declared by the client and recored by the personnel who collected the specimen.
- **Ref.Dr** - The name of the doctor who has recommended testing as declared by the client.
- **Labcode** - This is the accession number in our laboratory and it helps us in archiving and retrieving the data.
- **Barcode** - This is the specimen identity number and it states that the results are for the specimen bearing the barcode (irrespective of the name).
- **SCP** - Specimen Collection Point - This is the location where the blood or specimen was collected as declared by the client.
- **SCT** - Specimen Collection Time - The time when specimen was collected as declared by the client.
- **SRT** - Specimen Receiving Time - This time when the specimen reached our laboratory.
- **RRT** - Report Releasing Time - The time when our pathologist has released the values for Reporting.
- **Reference Range** - Means the range of values in which 95% of the normal population would fall.

SUGGESTIONS

- Values out of reference range requires reconfirmation before starting any medical treatment.
- Retesting is needed if you suspect any quality shortcomings.
- Testing or retesting should be done in accredited laboratories.
- For suggestions, complaints, clinical support or feedback, write to us at **customersupport@thyrocare.com** or call us on **022-3090 0000**





+ *T&C Apply, #As on 5th December 2024 (Applicable for all company owned labs except Bhagalpur & Vijayawada),*

⋆ *As per survey on doctors' perception of laboratory diagnostics (IJARIIT, 2023), -Mumbai Reference Lab is CAP Accredited*

Dummy Report